Basic HTML Version
VOLUME 9 NUMBER 1 • MARCH 2012
25
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
Acknowledgement
We acknowledge the Diabetic Association of Bangladesh and the
International Program in the Chemical Sciences (IPICS), Uppsala
University, Sweden for the financial support of this study.
References
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune
1.
system?
Diabetologia
1998;
41
: 1241–1248.
Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: A
2.
focus on subjects at risk for type 2 diabetes.
Curr Diab
2004;
4
: 237–246.
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S,
3.
et al
.
Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis
Risk in Communities study): a cohort study.
Lancet
1999;
353
: 1649–1652.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein,
4.
interleukin 6, and risk of developing type 2 diabetes mellitus.
J Am Med Assoc
2001;
286
: 327–334.
Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP.
5.
The relation of markers of inflammation to the development of glucose disorders
in the elderly: the Cardiovascular Health Study.
Diabetes
2001;
50
: 2384–2389.
Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD,
6.
et al
. C-reactive
protein is an independent predictor of risk for the development of diabetes in the
West of Scotland Coronary Prevention Study.
Diabetes
2002;
51
: 1596–1600.
Hotamisligil, GS. Tumor necrosis factor alpha inhibits signaling from the insulin
7.
receptor.
Proc Natl Acad Sci USA
1994;
91
: 4854–4858
Chen KT, Chen CJ, Gregg EW, Imperatore G, Narayan KM. Impaired fasting
8.
glucose and risk of diabetes in Taiwan, follow up over three years.
Diabetes Res
Clin Pract
2003;
60
(3): 177–182.
Stith RJL. Endocrine and carbohydrate responses to interleukin-6 in vivo.
9.
Circulatory Shock
1994;
44
: 210–215.
Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B,
10.
et al.
Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with
type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not
insulin responsiveness.
Diabetologia
2004;
47
: 1029–1037.
Miyazaki Y, Pipek R, Mandarino LJ, De Fronzo RA. Tumor necrosis factor alpha
11.
and insulin resistance in obese type 2 diabetic patients.
Int J Obes Relat Metab
Disord
2003;
27
: 88–94.
Konukoglu D, Hatemi H, Bayer H, Bagriacik N. Relation between serum
12.
concentrations of interleukin-6 and tumor necrosis factor-
α
in female Turkish
subjects with normal and impaired glucose tolerance.
Horm Metab Res
2006;
38
(1): 34–37.
Cardellini M, Andreozzi F, Laratta E, Marini MA, Lauro R, Hribal ML,
13.
et al
. Plasma
IL-6 levels are increased in subjects with impaired glucose tolerance but not in
those with impaired fasting glucose in a cohort of Italian Caucasians.
Diabetes
Metab Res
2007;
23
(2): 141–145.
Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment
14.
(HOMA) evaluation uses the computer program.
Diabetes Care
1998;
21
:
2191–2192.
Hotamisligil GS. Inflammatory pathways and insulin action.
15.
Int J Obes Relat
Metab Disord
2003;
27
(suppl 3): S53–S55.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-
16.
mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and
obesity-induced insulin resistance.
Science
1996;
271
: 665–668.
Sun Y, Liu S, Ferguson S, Wang L, Klepcyk P, Yun SJ, Friedman EJ. Phospho-
17.
enolpyruvate carboxykinase overexpression selectively attenuates insulin
signaling and hepatic insulin sensitivity in transgenic mice.
J Biol Chem
2002;
277
: 23301–23307.
Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of
18.
hepatic glucose metabolism in humans.
Recent Prog Horm Res
2001;
56
: 219–
237.
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M,
19.
et al.
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in
humans; Role of oxidative stress.
Circulation
2002;
106
: 2067–2072.
Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert
20.
B,
et al
. Impaired glucose tolerance is associated with increased serum
concentrations of interleukin-6 and co-regulated acute-phase proteins but not
TNF-a or its receptors.
Diabetologia
2002;
45
: 805–812.
Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG,
21.
et al
. Comparison of serum
concentrations of C-reactive protein, TNF-alpha and IL-6 between elderly
Korean women with normal and Impaired Glucose Tolerance.
Diabetes Res Clin
Pract
2004;
64
: 99–106.
Spranger J, Kroke A, Möhlig M, Ristow M, Boeing H, Pfeiffer AFH. Role of TNF-
22.
alpha in the development of type 2 diabetes: Preliminary results of a population-
based, prospective study.
Exp Clin Endocrinol Diabetes
2002;
II
: 194.
Diary for 2012 diabetes congresses
DATE
PLACE
CONFERENCE
19–22 April
Bantry Bay, South Africa
SEMDSA/NOFSA Congress
www.semdsa.org.za
5–9 May
Florence, Italy
European Congress of Endocrinology
8–12 June
Philadelphia, USA
72nd American Diabetes Association
Scientific Sessions
24–26 July
Johannesburg, South Africa CDE Centres for Diabetes and Endocrinology
10–13 October
Istanbul, Turkey
ISPAD 2012 – 38th Annual Meeting of
the International Society for Pediatric and
Adolescent Diabetes
4–6 December
Dubai, United Arab Emirates
1st American Diabetes Association Middle
East Congress ‘Diabetes Prevention and
Treatment’
It's the
shell that
makes
safer.
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.